This provides potential opportunities for targeting these pathways as therapeutic approaches to IDH mutant cancers, for example, targeting hypermethylation phenotype using epigenetic modulators [63,121,122]; targeting essential metabolic pathways, such as the NAD de novo synthesis pathway [131] or glutaminolysis [29,140]; targeting compromised DNA repair pathways in IDH mutant cancers [22,23,69,141]; and targeting redox regulators, such as NRF2 [25,27,28,128]. Here, IDH1 is linked to cancer.